Note: This document contains side effect information about alogliptin. Some of the dosage forms listed on this page may not apply to the brand name Nesina.
More frequent side effects include: upper respiratory tract infection, headache, and nasopharyngitis. See below for a comprehensive list of adverse effects.
Applies to alogliptin: oral tablet
Along with its needed effects, alogliptin (the active ingredient contained in Nesina) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking alogliptin:
Incidence not known
Some side effects of alogliptin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to alogliptin: oral tablet
The most frequently reported side effects included nasopharyngitis, headache, and upper respiratory tract infection.
Common (1% to 10%): Abdominal pain, gastroesophageal reflux disease
Uncommon (0.1% to 1%): Pancreatitis
Postmarketing reports: Acute pancreatitis, diarrhea, constipation, nausea, ileus
During clinical trials, acute pancreatitis was reported in 6 (0.2%) patients receiving 25 mg and 2 patients (less than 0.1%) who were treated with active comparators or placebo. In a cardiovascular outcome trial of patient with high cardiovascular risk, acute pancreatitis was reported in 10 patients receiving this drug and 7 patients receiving placebo (0.4% vs 0.3%).
Frequency not reported: Arthralgia
Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database. Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor. In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain. In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation. A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor. Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).
Postmarketing reports: Hepatic enzyme elevations, fulminant hepatic failure
Uncommon (0.1% to 1%): Hypersensitivity reactions (0.6%)
Postmarketing reports: Anaphylaxis, angioedema, rash, urticaria, severe cutaneous adverse reactions (Stevens-Johnson syndrome)
Common (1% to 10%): Headache
Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection
Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use. These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.
Common (1% to 10%): Pruritus, rash
Postmarketing reports: Exfoliative skin conditions including Stevens-Johnson syndrome, erythema multiforme, angioedema, urticaria
Dipeptidyl peptidase-4 inhibitors:
Postmarketing reports: Bullous pemphigoid
Common (1% to 10%): Hypoglycemia
Based on a pooled analysis the hypoglycemic risk of this drug was considered neutral.
Frequency not reported: Heart failure
In a clinical trial in patients with recent acute coronary syndrome, a greater proportion of patients receiving this drug were hospitalized for congestive heart failure compared with placebo (3.9% [n=106] vs 3.3% [n=89]),
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Nesina